"Thiophenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013876
|
| MeSH Number(s) |
D02.886.778 D03.383.903
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiophenes".
Below are MeSH descriptors whose meaning is more specific than "Thiophenes".
This graph shows the total number of publications written about "Thiophenes" by people in this website by year, and whether "Thiophenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 4 | 5 |
| 2012 | 1 | 2 | 3 |
| 2013 | 3 | 2 | 5 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 3 | 6 |
| 2016 | 0 | 1 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiophenes" by people in Profiles.
-
Contralesional angiotensin type 2 receptor activation contributes to recovery in experimental stroke. Neurochem Int. 2022 09; 158:105375.
-
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun; 22(4):671-681.
-
Stimulation of angiotensin II receptor 2 preserves cognitive function and is associated with an enhanced cerebral vascular density after stroke. Vascul Pharmacol. 2021 12; 141:106904.
-
Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain. J Comp Eff Res. 2021 10; 10(15):1107-1119.
-
Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization. Transl Stroke Res. 2020 08; 11(4):762-775.
-
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
-
Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study. Am J Physiol Heart Circ Physiol. 2019 05 01; 316(5):H1192-H1201.
-
Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals-A randomized double- blind pre-clinical study. Behav Brain Res. 2019 02 01; 359:560-569.
-
RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018 Aug 13; 15(1):229.
-
Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2019 08; 39(8):1635-1647.